IOL Chemicals & Pharmaceuticals
add_icon

IOL Chemicals & Pharmaceuticals

68.13
-0.53
(-0.77%)
Market Cap
1,999.80 Cr
PE Ratio
17.34
Volume
7,24,814.00
Day High - Low
69.69 - 68.00
52W High-Low
126.66 - 57.50
hide
Key Fundamentals
Add Ratio
split_icon_default
Market Cap
1,999.80 Cr
EPS
3.44
PE Ratio
17.34
PB Ratio
1.15
Book Value
59.66
EBITDA
224.70
Dividend Yield
1.17 %
Industry
Healthcare
Return on Equity
5.99
Debt to Equity
0.05
Analyst Rating and Forecast
- By Refinitiv from2 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+100.00 %
+100.00 %
Hold
Hold0.0 %
0.0 %
Sell
Sell0.0 %
0.0 %
Forecast For
Actual

Company News

View All News
Caret
neutral
NM Merchantiles Limited acquired 1,17,41,100 equity shares of IOL Chemicals and Pharmaceuticals Limited through merger with Vasudeva Commercials, increasing its holding from 13.08% to 17.08%.
positive
IOL Chemicals and Pharmaceuticals Limited receives Certificate of Suitability from European Directorate for the Quality of Medicines for Metformin Hydrochloride Process-II, expanding its regulatory approvals for the antidiabetic API.
positive
IOL Chemicals increases ethyl acetate capacity to 120,000 MTPA and acetic anhydride capacity to 32,000 MTPA with ₹57.1 million investment, strengthening its chemical manufacturing capabilities.
View more
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,786.90
#1 4,28,737.17
39.05
#1 54,729.00
9.71
#1 10,980
16.07
56.64
6,057.00
1,60,794.32
65.06
9,712.00
18.67
2,191
-1.02
38.37
4,278.10
1,44,790.34
63.50
11,539.40
6.99
1,911
26.24
49.65
1,266.90
1,05,739.32
19.27
33,741.20
16.73
5,725
-15.28
47.81
2,294.30
1,04,803.35
22.42
22,909.50
13.74
3,306
#1 37.44
53.17
1,276.70
1,03,128.23
23.14
28,409.50
7.12
5,291
-57.18
36.50
890.75
89,630.29
#1 17.74
23,511.00
18.55
4,615
-0.32
42.14
2,077.10
85,743.74
47.89
12,744.20
#1 20.90
2,007
7.65
43.63
1,277.90
74,220.64
21.32
32,345.60
9.43
3,484
7.59
61.70
5,322.50
63,638.47
26.27
13,458.30
3.70
2,216
1.90
39.37
Growth Rate
Revenue Growth
-2.83 %
Net Income Growth
-24.78 %
Cash Flow Change
-38.36 %
ROE
-28.18 %
ROCE
-26.58 %
EBITDA Margin (Avg.)
-11.29 %

Quarterly Financial Results

Quarterly Financials
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Dec 2025
Revenue
579
570
547
530
596
570
552
529
511
510
532
527
532
559
574
586
Expenses
527
509
510
481
492
491
481
476
454
451
484
476
465
490
511
534
EBITDA
52
61
37
49
104
80
71
53
57
59
48
51
67
70
64
51
Operating Profit %
8 %
10 %
6 %
8 %
16 %
13 %
12 %
9 %
10 %
10 %
8 %
9 %
12 %
11 %
10 %
8 %
Depreciation
11
11
11
12
12
14
16
16
16
17
18
19
19
20
20
20
Interest
2
3
4
5
5
4
4
4
3
2
4
5
4
4
4
4
Profit Before Tax
39
47
22
33
87
61
51
32
37
40
26
28
45
46
41
28
Tax
9
12
6
9
22
15
13
9
10
10
7
7
13
12
11
7
Net Profit
30
35
16
24
65
46
38
23
28
30
19
21
31
34
30
21
EPS in ₹
5.07
5.91
2.71
4.05
11.03
7.81
6.45
3.93
4.71
5.11
3.26
3.50
1.07
1.16
1.02
0.70

Balance Sheet

Balance Sheet
2022
2023
2024
2025
Total Assets
1,962
2,022
2,244
2,382
Fixed Assets
561
752
933
1,171
Current Assets
1,081
920
1,120
1,151
Capital Work in Progress
105
90
101
22
Investments
2
20
20
21
Other Assets
1,294
1,161
1,190
1,169
Total Equity & Liabilities
1,962
2,022
2,244
2,382
Current Liabilities
513
456
560
610
Non Current Liabilities
57
58
73
85
Total Equity
1,392
1,508
1,612
1,688
Reserve & Surplus
1,334
1,449
1,553
1,629
Share Capital
59
59
59
59

Cash Flow

Cash Flow
2022
2023
2024
2025
Net Cash Flow
-29
-2
6
71
Investing Activities
-121
-120
-191
-154
Operating Activities
93
122
290
179
Financing Activities
-2
-4
-93
46

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Dec 2025
Promoter
43.69 %
43.69 %
43.69 %
43.69 %
43.69 %
43.69 %
43.69 %
43.69 %
48.19 %
48.19 %
48.19 %
48.19 %
48.19 %
48.19 %
48.19 %
52.62 %
52.62 %
52.62 %
52.62 %
52.62 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
2.34 %
2.18 %
1.41 %
1.39 %
1.63 %
1.49 %
1.47 %
2.59 %
2.25 %
2.08 %
DIIs
0.04 %
0.04 %
0.36 %
0.50 %
0.02 %
0.02 %
0.06 %
0.17 %
0.02 %
0.26 %
0.36 %
0.37 %
0.30 %
0.10 %
0.08 %
0.08 %
0.07 %
0.02 %
0.04 %
0.03 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
27.30 %
28.03 %
29.86 %
30.15 %
30.29 %
31.15 %
31.15 %
30.92 %
30.49 %
29.28 %
30.28 %
30.63 %
30.98 %
31.48 %
31.31 %
31.23 %
31.43 %
30.22 %
29.97 %
30.51 %
Others
28.97 %
28.24 %
26.08 %
25.66 %
25.99 %
25.14 %
25.10 %
25.23 %
21.30 %
22.26 %
18.84 %
18.62 %
19.12 %
18.84 %
18.79 %
14.58 %
14.40 %
14.54 %
15.12 %
14.76 %
No of Share Holders
1,09,092
1,27,893
1,42,022
1,45,041
1,46,437
1,48,907
1,45,692
1,43,327
1,40,177
1,26,004
1,35,397
1,34,235
1,30,003
1,28,689
1,25,979
1,26,701
1,30,002
1,25,040
1,36,129
1,33,531

Dividend History

Annual Cash Flows 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Dividend Per Share (₹) 0.00 0.00 0.00 3 6 4 4 5 0.8 0.00
Dividend Yield (%) 0.00 0.00 0.00 2.72 8.48 7.07 5.53 8.18 1.17 0.00

Announcements

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 201110 days ago
EDQM Issued CEP Certificate For METFORMIN HYDROCHLORIDE Process-II10 days ago
Disclosure Pursuant To Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Mar 02, 2026
EDQM Issued CEP Certificate For CLOPIDOGREL BESILATEFeb 24, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 18, 2026
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 18, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 12, 2026
Intimation On Communication To Members Regarding Tax Deducted At Source For Interim DividendFeb 12, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 12, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 12, 2026
Announcement under Regulation 30 (LODR)-Investor PresentationFeb 12, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 11, 2026
Corporate Action-Board approves DividendFeb 11, 2026
Board Meeting Outcome for Outcome Of The Board Meeting And Submission Of Un-Audited Financial Results For The Quarter And Nine Months Ended 31St December 2025Feb 11, 2026
Un-Audited Financial Results For The Quarter And Nine Months Ended 31St December 2025Feb 11, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 04, 2026
Disclosure Pursuant To Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jan 27, 2026
Board Meeting Intimation for Notice Of The Board MeetingJan 23, 2026
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 08, 2026
Closure of Trading WindowDec 29, 2025
EDQM Issued CEP Certificate For MINOXIDILDec 05, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 26, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptNov 19, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 13, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationNov 12, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 12, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 11, 2025
Un-Audited Financial Results For The Quarter And Half Year Ended 30Th September 2025Nov 11, 2025
Board Meeting Outcome for Outcome Of The Board Meeting And Submission Of Un-Audited Financial Results For The Quarter And Half Year Ended 30Th September 2025Nov 11, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 10, 2025
Board Meeting Intimation for Notice Of Board MeetingNov 04, 2025
EDQM Issued CEP Certificate For Sitagliptin Phosphate MonohydrateOct 27, 2025
Intimation Of Incorporation Of Wholly Owned SubsidiaryOct 24, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Oct 18, 2025
EDQM Issued CEP Certificate For Pantoprazole Sodium Sesquihydrate Process-IIIOct 15, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 07, 2025
Intimation On Receipt Of Request For Re-Lodgement Of Transfer Requests Of Physical SharesOct 01, 2025
Closure of Trading WindowSep 26, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 25, 2025
Dispatch Of Reminder Letter To Shareholders To Update KYCSep 24, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 09, 2025
Clarification On Volume MovementSep 09, 2025
Clarification sought from IOL Chemicals & Pharmaceuticals LtdSep 09, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 29, 2025
Shareholder Meeting / Postal Ballot-Scrutinizers ReportAug 22, 2025
Shareholder Meeting / Postal Ballot-Outcome of AGMAug 22, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 13, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 12, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 12, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 08, 2025

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
Motilal Oswal BSE 1000 Index Fund Direct-Growth
0.00%
4
0.00%
0.00%
Bandhan BSE Healthcare Index Fund Direct-Growth
0.06%
0
0.00%
-0.01%

Technical Indicators

RSI(14)
Neutral
38.20
ATR(14)
Volatile
2.84
STOCH(9,6)
Neutral
28.63
STOCH RSI(14)
Oversold
17.10
MACD(12,26)
Bearish
-0.27
ADX(14)
Weak Trend
10.31
UO(9)
Bearish
46.70
ROC(12)
Downtrend And Accelerating
-8.18
WillR(14)
Oversold
-82.42